STEP-HFpEF: semaglutide in heart failure with preserved EF

GenomicsKate said:

The mechanism that matters here is not stomach emptying, it is central.

Thank you — that is the clearest version of this I have read, and I have read a lot of them. Printing the relevant bit and taking it with me.

Adding the clinical framing, because it changes how the question reads.

Cardiac biomarkers and cardiovascular risk: my cardiologist ordered advanced cardiac labs given my family history. Results were encouraging:

• NT-proBNP: 51 pg/mL (normal, cardiac function preserved)
• Lp(a): 31 nmol/L (genetic, unchanged — expected)
• ApoB: dropped from 146 to 91 mg/dL (excellent response)
• Coronary calcium score: 0 (unchanged from baseline — reassuring)

The ApoB reduction is particularly meaningful — it's considered the best single predictor of cardiovascular risk. GLP-1 therapy seems to improve this consistently.

Dr.ReproEndo said:

The dose-response is real but shallow at the top.

I read this differently from Dr.ReproEndo, on substance rather than tone. The trial means are being read too generously in this thread. STEP populations were selected, supported, and titrated by protocol, and the real-world curves are consistently a few points worse. That difference is not noise, it is what happens when you remove the study infrastructure.

Dr.CardioMD said:

SELECT is the trial that changed the framing of this class, because it was an outcome trial rather than a weight trial: about a 20% relative reduction…

Senior perspective on cardiovascular risk: I'm 71 years old and started this journey skeptically. My geriatrician recommended it after years of failed interventions.

9 months later: down 54 lbs, more mobile, pain reduced, medications simplified. My quality of life has improved dramatically. I wish this existed 20 years ago.

To other older adults hesitating: the SELECT trial proved benefit in our age group. You deserve to feel good in your body regardless of age.

Moderator note: a couple of off-topic posts removed.